TRM - 201 (rofecoxib) is being developed as a fast-track, first approved treatment for Hemophilic Arthropathy, a serious orphan disease for which high-potency opioids are the current standard of care.

  • The clinical development plan for TRM - 201 has been confirmed with the FDA

  • Orphan designation has been granted by the FDA and is accessible via this LINK

  • Additional follow-on indications are being explored